A number of research firms have changed their ratings and price targets for Allergan (NYSE: AGN):

  • 12/12/2017 – Allergan was given a new $191.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 12/7/2017 – Allergan was downgraded by analysts at Argus from a “buy” rating to a “hold” rating. They now have a $160.07 price target on the stock, down previously from $256.80.
  • 12/6/2017 – Allergan was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $187.73 price target on the stock.
  • 12/6/2017 – Allergan was given a new $200.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 12/6/2017 – Allergan had its “buy” rating reaffirmed by analysts at Wells Fargo & Company.
  • 12/4/2017 – Allergan was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating.
  • 12/2/2017 – Allergan was given a new $191.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/29/2017 – Allergan was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $200.00 price target on the stock, up previously from $171.92.
  • 11/27/2017 – Allergan had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $237.00 price target on the stock.
  • 11/2/2017 – Allergan had its price target lowered by analysts at Morgan Stanley from $228.00 to $200.00. They now have an “equal weight” rating on the stock.
  • 11/2/2017 – Allergan had its price target lowered by analysts at Cantor Fitzgerald to $191.00. They now have a “neutral” rating on the stock.
  • 11/2/2017 – Allergan had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $245.00 price target on the stock, down previously from $258.00.
  • 11/2/2017 – Allergan had its price target lowered by analysts at Royal Bank of Canada from $250.00 to $221.00. They now have an “outperform” rating on the stock.
  • 11/1/2017 – Allergan was given a new $231.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/29/2017 – Allergan was given a new $250.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 10/23/2017 – Allergan was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions. Key products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Though Allergan’s shares have declined this year so far, they have performed better than the industry. Estimates have declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 10/22/2017 – Allergan was given a new $275.00 price target on by analysts at J P Morgan Chase & Co. They now have a “buy” rating on the stock.
  • 10/20/2017 – Allergan was given a new $280.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 10/19/2017 – Allergan had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $250.00 price target on the stock, down previously from $277.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 10/19/2017 – Allergan had its price target lowered by analysts at Citigroup Inc. from $280.00 to $240.00. They now have a “buy” rating on the stock.
  • 10/19/2017 – Allergan was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $193.00 price target on the stock.
  • 10/18/2017 – Allergan had its “hold” rating reaffirmed by analysts at Edward Jones.
  • 10/18/2017 – Allergan was given a new $252.00 price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 10/18/2017 – Allergan had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $258.00 price target on the stock.
  • 10/17/2017 – Allergan was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Allergan’s products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, Allergan is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. In October, a Texas federal district court invalidated four of the six patents covering Restasis, Allergan’s second best-selling drug, potentially opening doors for early generic competition. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares have underperformed the broader industry in the past one month.  Estimates have also declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 10/17/2017 – Allergan was given a new $251.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 10/17/2017 – Allergan was given a new $255.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 10/17/2017 – Allergan was given a new $243.00 price target on by analysts at Credit Suisse Group AG. They now have an “outperform” rating on the stock.
  • 10/16/2017 – Allergan had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $275.00 price target on the stock.

Shares of Allergan PLC. (AGN) opened at $170.94 on Friday. The firm has a market capitalization of $56,286.37, a P/E ratio of 10.98, a PEG ratio of 1.13 and a beta of 1.11. Allergan PLC. has a 1 year low of $160.07 and a 1 year high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $3.32 EPS. equities research analysts anticipate that Allergan PLC. will post 16.27 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be given a $0.70 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.64%. Allergan’s dividend payout ratio is currently -12.44%.

In related news, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Chris W. Bodine purchased 3,030 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were purchased at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 17,630 shares of company stock worth $2,890,057. Corporate insiders own 0.36% of the company’s stock.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.